Press Release

<< Back
April 21, 2020 at 5:18 PM EDT

Verastem Oncology Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

BOSTON--(BUSINESS WIRE)--Apr. 21, 2020-- Verastem, Inc. (NASDAQ: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that in light of public health and safety precautions related to COVID-19, including restrictions on in-person gatherings, the Company’s 2020 annual meeting of stockholders will be changed from an in-person meeting to a virtual-only meeting. As previously announced, the annual meeting will be held on May 19, 2020 at 9 a.m. Eastern Time, but stockholders will not be able to attend in person. The virtual meeting will provide stockholders with the ability to participate, vote their shares, and ask questions.

As described in the proxy materials for the annual meeting previously distributed, you are entitled to participate in the annual meeting if you were a stockholder of record as of on March 23, 2020, the record date for the annual meeting.

To gain access to the meeting, you must go to the meeting website at www.virtualshareholdermeeting.com/VSTM2020 (website will be active prior to the meeting) and enter the 16-digit control number provided on the proxy card, voting instruction form or notice regarding the availability of proxy materials previously received. The virtual meeting website will contain participation instructions.

Whether or not planning to attend the annual meeting, stockholders are encouraged to vote in advance of the annual meeting by one of the methods described in the proxy materials. Stockholders who have previously voted do not need to take any further action. The proxy card and voting instruction form included with the previously distributed proxy materials will not be updated to reflect the change from an in-person meeting to a virtual-only meeting and may continue to be used to vote shares in connection with the annual meeting.

For further information, please refer to the Company’s proxy statement and notice regarding the availability of proxy materials, filed with the SEC on April 8, 2020, each of which can be accessed at https://investor.verastem.com/financial-information/sec-filings.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and RAF/MEK inhibition.

Our first FDA approved product is available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).

For more information, please visit www.verastem.com.

Verastem Oncology:
Investors:
John Doyle
Vice President, Investor Relations & Finance
+1 781-469-1546
jdoyle@verastem.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

Source: Verastem, Inc.

Investor Contact

getty
John Doyle

VP Investor Relations & Finance
781.292.4279
jdoyle@verastem.com

Joe Rayne

Argot Partners
617.340.6075
joseph@argotpartners.com